Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44416   clinical trials with a EudraCT protocol, of which   7423   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    The efficacy and mechanism of surfactant therapy for critically ill infants with bronchiolitis: The Bronchiolitis Endotracheal Surfactant Study (BESS)

    Summary
    EudraCT number
    2018-001169-18
    Trial protocol
    GB  
    Global end of trial date
    03 Apr 2024

    Results information
    Results version number
    v1(current)
    This version publication date
    13 Nov 2026
    First version publication date
    13 Nov 2026
    Other versions
    Summary report(s)
    BESS Protocol_V7.0 19.03.2025 Signed.pdf
    BESS - Final_Analysis_Report_v5.0_20260311.pdf

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    UoL001360
    Additional study identifiers
    ISRCTN number
    ISRCTN11746266
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Other trial identifiers
    IRAS Reference: 220853, REC Reference: 18/SC/0427
    Sponsors
    Sponsor organisation name
    The University of Liverpool
    Sponsor organisation address
    Clinical Directorate, 4th Floor Thompson Yates Building, Faculty of Health and Life Sciences , Liverpool, United Kingdom, L3 5RB
    Public contact
    BESS Trial, Clinical Trials Research Centre (CTRC), 44 0151 795 8757, bess@liverpool.ac.uk
    Scientific contact
    BESS Trial, Clinical Trials Research Centre (CTRC), 44 0151 795 8757, bess@liverpool.ac.uk
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    13 Dec 2024
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    03 Apr 2024
    Global end of trial reached?
    Yes
    Global end of trial date
    03 Apr 2024
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    BESS is a study that comprises three work packages. The Trial is Work Package A (WP-A), the parent and staff experience substudy is work package B (WP-B) and the mechanistic substudy is work package C (WP-C). The hypothesis we are testing in The Trial (WP-A) is: Endotracheal surfactant reduces duration of mechanical ventilation by 18 hours. This trial will test whether giving surfactant into the lungs of babies suffering from severe bronchiolitis reduces the time they spend on a mechanical ventilator to help them breathe. We will do this by measuring the total time babies spend on a mechanical ventilator in hours and comparing the time required by babies given a surfactant (called poractant alfa) to babies given air (a dummy or placebo treatment). "18 hours" is included in the hypothesis as this is considered to be the smallest period of time that would be of benefit to a baby's wellbeing. The study will run over 3 winter seasons and involve about 284 babies.
    Protection of trial subjects
    Administration of poractant alfa (porcine derived surfactant, Curosurf®) in infants with bronchiolitis is well tolerated and considered safe. Transient minor adverse reactions associated with administration of poractant alfa for the treatment of neonatal Respiratory Distress Syndrome (RDS) include bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation. The risk of such events is minimised by tracheal toilet prior to administration of poractant alfa, as recommended in the Summary of Product Characteristics. Small volume (2x1mL/kg) non-bronchoscopic bronchoalveolar lavage (BAL) procedure on PICU is safe and well tolerated procedure. In a published audit of 27 children on PICU who underwent multiple small volume BAL installations (5x1mL/kg) as part of a single routine diagnostic procedure, 7 experienced transient oxygen desaturation requiring temporary increased FiO2. We will limit BAL sampling to a 2x1mL/kg instillation at each scheduled assessment. BAL sampling for this research study will cease on approval of v5 of this protocol. Small volume (1.25mL (range 1.0 to 1.3mL)) blood sampling will be done on infants ventilated at Liverpool and Southampton PICUs and scheduled to coincide with routine blood sampling. Existing vascular access will be used when available. There is no risk of anaemia associated with this limited volume of blood sampling. The sample will be taken from an arterial line if present. If not by standard venesection. This additional blood sampling at Liverpool and Southampton PICUs will cease on approval of v5 of this protocol. Capillary blood gas sampling or arterial blood gas sampling for subject monitoring (100microliters) will use data from routine blood gas sampling when either is collected within a 4-hour (+/-2hrs) window of a research-scheduled sample. As this is part of standard care no additional risks are expected.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    01 Nov 2018
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United Kingdom: 232
    Worldwide total number of subjects
    232
    EEA total number of subjects
    0
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    6
    Newborns (0-27 days)
    110
    Infants and toddlers (28 days-23 months)
    116
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    1009 patient were screened for eligibility. 391 of these were ineligible at screening, 618 were eligible. Of the 618 eligible at screening patients, 232 were randomised.

    Pre-assignment period milestones
    Number of subjects started
    1009 [1]
    Number of subjects completed
    232

    Pre-assignment subject non-completion reasons
    Reason: Number of subjects
    Ineligible at screening: 391
    Reason: Number of subjects
    Eligible but not approached: 264
    Reason: Number of subjects
    Declined to participate: 103
    Reason: Number of subjects
    Not randomised: 18
    Reason: Number of subjects
    Incomplete screening log: 1
    Notes
    [1] - The number of subjects reported to have started the pre-assignment period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
    Justification: 1009 patient were screened for eligibility. 391 of these were ineligible at screening, 618 were eligible. Of the 618 eligible at screening patients, 232 were randomised i.e. the worldwide number enrolled in the trial.
    Period 1
    Period 1 title
    Baseline (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Carer, Assessor

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Endotracheal poractant alfa
    Arm description
    -
    Arm type
    Experimental

    Investigational medicinal product name
    Endotracheal poractant alfa
    Investigational medicinal product code
    Other name
    Curosurf®
    Pharmaceutical forms
    Endotracheopulmonary instillation
    Routes of administration
    Endotracheopulmonary use
    Dosage and administration details
    Endotracheal poractant alfa (Curosurf®, porcine lung phospholipid fraction supplied at 80mg/mL), first dose 200mg/kg, repeated 12 hourly at 100mg/kg, up to a total of 3 doses according to the manufacturer's summary of product characteristics (SPC).

    Arm title
    Sham Intervention group
    Arm description
    -
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Endotracheopulmonary instillation
    Routes of administration
    Endotracheopulmonary use
    Dosage and administration details
    An identical (to the experimental arm) series of up to three procedures (while intubated) using air as the placebo

    Number of subjects in period 1
    Endotracheal poractant alfa Sham Intervention group
    Started
    115
    117
    Completed
    113
    116
    Not completed
    2
    1
         Withdrawn prior to experiencing primary outcome
    2
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Endotracheal poractant alfa
    Reporting group description
    -

    Reporting group title
    Sham Intervention group
    Reporting group description
    -

    Reporting group values
    Endotracheal poractant alfa Sham Intervention group Total
    Number of subjects
    115 117 232
    Age categorical
    Age corrected for gestation
    Units: Subjects
        In utero
    0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    4 2 6
        Newborns (0-27 days)
    53 57 110
        Infants and toddlers (28 days-23 months)
    58 58 116
        Children (2-11 years)
    0 0 0
        Adolescents (12-17 years)
    0 0 0
        Adults (18-64 years)
    0 0 0
        From 65-84 years
    0 0 0
        85 years and over
    0 0 0
    Age continuous
    Chronological age- not corrected for premature birth
    Units: weeks
        arithmetic mean (standard deviation)
    9.1 ( 7.5 ) 9.2 ( 7.0 ) -
    Gender categorical
    Units: Subjects
        Female
    52 50 102
        Male
    63 67 130
    Premature (yes/ no)
    Units: Subjects
        Yes
    66 61 127
        No
    49 56 105
    Intubated on arrival to PICU (yes/ no)
    Units: Subjects
        Yes
    90 97 187
        No
    25 20 45
    O2 supplementation on arrival to PICU
    Units: Subjects
        Yes
    113 115 228
        No
    1 2 3
        Data unobtainable
    1 0 1
    Underlying viral infection identified:
    Units: Subjects
        Yes
    101 111 212
        No infection identified
    8 5 13
        No sample
    4 0 4
        Data unobtainable
    2 1 3
    Underlying bacterial infection identified:
    Units: Subjects
        Yes
    29 31 60
        No infection identified
    79 82 161
        No sample
    4 2 6
        Data unobtainable
    3 2 5
    Chronological age- not corrected for premature birth
    Units: weeks
        median (inter-quartile range (Q1-Q3))
    6.0 (5.0 to 12.0) 8.0 (4.0 to 12.0) -
    Chronological age- not corrected for premature birth
    Units: weeks
        median (full range (min-max))
    6.0 (1.0 to 42.0) 8.0 (1.0 to 37.0) -
    Age corrected for prematurity (weeks)
    Units: weeks
        arithmetic mean (standard deviation)
    5.0 ( 6.5 ) 4.8 ( 5.9 ) -
    Age corrected for prematurity (weeks)
    Units: weeks
        median (inter-quartile range (Q1-Q3))
    4.0 (0.0 to 8.0) 3.0 (1.0 to 7.0) -
    Age corrected for prematurity (weeks)
    Units: weeks
        median (full range (min-max))
    4.0 (-5.0 to 25.0) 3.0 (-4.0 to 23.0) -
    Weight (Kg)
    Baseline weight in Kg: 115 of 115 Endotracheal poractant alfa participants had weight measured at baseline, data was unobtainable for 0 participants. 116 of 117 Sham Intervention group participants had weight measured at baseline, data was unobtainable for 1 participant.
    Units: Kg
        arithmetic mean (standard deviation)
    4.2 ( 1.5 ) 4.2 ( 1.5 ) -
    Weight (Kg)
    Baseline weight in Kg: 115 of 115 Endotracheal poractant alfa participants had weight measured at baseline, data was unobtainable for 0 participants. 116 of 117 Sham Intervention group participants had weight measured at baseline, data was unobtainable for 1 participant.
    Units: Kg
        median (inter-quartile range (Q1-Q3))
    4.0 (3.0 to 5.0) 4.0 (3.1 to 5.0) -
    Weight (Kg)
    Baseline weight in Kg: 115 of 115 Endotracheal poractant alfa participants had weight measured at baseline, data was unobtainable for 0 participants. 116 of 117 Sham Intervention group participants had weight measured at baseline, data was unobtainable for 1 participant.
    Units: Kg
        median (full range (min-max))
    4.0 (2.0 to 8.9) 4.0 (2.0 to 8.8) -
    Time on mechanical ventilator prior to arrival at PICU (hours)
    Baseline time on mechanical ventilator prior to arrival at PICU (hours): 111 of 115 Endotracheal poractant alfa participants had time on mechanical ventilator prior to arrival at PICU (hours) measured at baseline, data was unobtainable for 4 participants. 116 of 117 Sham Intervention group participants had time on mechanical ventilator prior to arrival at PICU (hours) measured at baseline, data was unobtainable for 1 participant.
    Units: Hours
        arithmetic mean (standard deviation)
    29.4 ( 9.4 ) 29.4 ( 10.4 ) -
    Time on mechanical ventilator prior to arrival at PICU (hours)
    Baseline time on mechanical ventilator prior to arrival at PICU (hours): 111 of 115 Endotracheal poractant alfa participants had time on mechanical ventilator prior to arrival at PICU (hours) measured at baseline, data was unobtainable for 4 participants. 116 of 117 Sham Intervention group participants had time on mechanical ventilator prior to arrival at PICU (hours) measured at baseline, data was unobtainable for 1 participant.
    Units: Hours
        median (inter-quartile range (Q1-Q3))
    30.1 (22.7 to 37.0) 29.9 (21.3 to 37.1) -
    Time on mechanical ventilator prior to arrival at PICU (hours)
    Baseline time on mechanical ventilator prior to arrival at PICU (hours): 111 of 115 Endotracheal poractant alfa participants had time on mechanical ventilator prior to arrival at PICU (hours) measured at baseline, data was unobtainable for 4 participants. 116 of 117 Sham Intervention group participants had time on mechanical ventilator prior to arrival at PICU (hours) measured at baseline, data was unobtainable for 1 participant.
    Units: Hours
        median (full range (min-max))
    30.1 (9.1 to 47.5) 29.9 (4.1 to 47.6) -

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Endotracheal poractant alfa
    Reporting group description
    -

    Reporting group title
    Sham Intervention group
    Reporting group description
    -

    Subject analysis set title
    Endotracheal poractant alfa (Safety set)
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    Endotracheal poractant alfa (Safety set)

    Subject analysis set title
    Sham Intervention group (Safety set)
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    Sham Intervention group (Safety set)

    Subject analysis set title
    Endotracheal poractant alfa (patient reported readmission)
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Patients randomised to Endotracheal poractant alfa and completed the patient reported readmission to hospital.

    Subject analysis set title
    Sham Intervention group (patient reported readmission)
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Patients randomised to Sham Intervention group and completed the patient reported readmission to hospital.

    Subject analysis set title
    Endotracheal poractant alfa (baseline weight)
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Endotracheal poractant alfa (baseline weight) - 115 of 115 Endotracheal poractant alfa participants had weight measured at baseline, data was unobtainable for 0 participants

    Subject analysis set title
    Sham Intervention group (baseline weight)
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Sham Intervention group (baseline weight) - 116 of 117 Sham Intervention group participants had weight measured at baseline, data was unobtainable for 1 participant

    Subject analysis set title
    Endotracheal poractant alfa (baseline time on ventilator)
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Endotracheal poractant alfa (baseline time on mechanical ventilator prior to arrival at PICU (hours)) - 111 of 115 Endotracheal poractant alfa participants had time on mechanical ventilator prior to arrival at PICU (hours) measured at baseline, data was unobtainable for 4 participants.

    Subject analysis set title
    Sham Intervention group (baseline time on ventilator)
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Sham Intervention group (baseline time on mechanical ventilator prior to arrival at PICU (hours)) - 116 of 117 Sham Intervention group had time on mechanical ventilator prior to arrival at PICU (hours) measured at baseline, data was unobtainable for 1 participant.

    Primary: Primary outcome – Total duration of mechanical ventilation in hours - Time to successful extubation - Median (IQR)

    Close Top of page
    End point title
    Primary outcome – Total duration of mechanical ventilation in hours - Time to successful extubation - Median (IQR)
    End point description
    A more extensive summary of results for this outcome can be found in the attached BESS - Final_Analysis_Report_v5.0_20260311.pdf.
    End point type
    Primary
    End point timeframe
    Date/time of randomisation to date/time of successful extubation.
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    113
    116
    Units: hours
        median (inter-quartile range (Q1-Q3))
    64.9 (43.2 to 92.1)
    62.0 (39.3 to 95.1)
    Statistical analysis title
    Two-sample t-test for log time on MV in hours
    Comparison groups
    Sham Intervention group v Endotracheal poractant alfa
    Number of subjects included in analysis
    229
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.8625
    Method
    t-test, 2-sided
    Parameter type
    Mean difference (final values)
    Point estimate
    0.02
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.18
         upper limit
    0.21

    Primary: Primary outcome – Total duration of mechanical ventilation in hours - Time to successful extubation - Median (Range)

    Close Top of page
    End point title
    Primary outcome – Total duration of mechanical ventilation in hours - Time to successful extubation - Median (Range)
    End point description
    End point type
    Primary
    End point timeframe
    Date/time of randomisation to date/time of successful extubation.
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    113
    116
    Units: hours
        median (full range (min-max))
    64.9 (1.9 to 500.3)
    62.0 (12.6 to 1631.6)
    Statistical analysis title
    Two-sample t-test for log time on MV in hours
    Comparison groups
    Endotracheal poractant alfa v Sham Intervention group
    Number of subjects included in analysis
    229
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.8625
    Method
    t-test, 2-sided
    Parameter type
    Mean difference (final values)
    Point estimate
    0.02
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.18
         upper limit
    0.21

    Primary: Primary outcome – Total duration of mechanical ventilation (MV) in hours

    Close Top of page
    End point title
    Primary outcome – Total duration of mechanical ventilation (MV) in hours
    End point description
    End point type
    Primary
    End point timeframe
    Date/time of randomisation to date/time of successful extubation.
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    113
    116
    Units: log time on MV (hours)
        arithmetic mean (confidence interval 95%)
    4.14 (4.01 to 4.28)
    4.13 (3.99 to 4.27)
    Statistical analysis title
    Two-sample t-test for log time on MV in hours
    Comparison groups
    Endotracheal poractant alfa v Sham Intervention group
    Number of subjects included in analysis
    229
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.8625
    Method
    t-test, 2-sided
    Parameter type
    Mean difference (final values)
    Point estimate
    0.02
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.18
         upper limit
    0.21
    Statistical analysis title
    Fixed Effects- log time on MV (hours) - Allocation
    Comparison groups
    Endotracheal poractant alfa v Sham Intervention group
    Number of subjects included in analysis
    229
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.8806
    Method
    ANCOVA
    Parameter type
    Endotracheal poractant- Treatment effect
    Point estimate
    0.01
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.17
         upper limit
    0.2
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.09

    Secondary: Secondary outcome 1 – Readiness for SBT - Time to readiness for SBT in hours

    Close Top of page
    End point title
    Secondary outcome 1 – Readiness for SBT - Time to readiness for SBT in hours
    End point description
    A more extensive summary of results for this outcome can be found in the attached BESS - Final_Analysis_Report_v5.0_20260311.pdf.
    End point type
    Secondary
    End point timeframe
    Date/time of randomisation to the date/time of the observation at which readiness for SBT is first reported.
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    98
    104
    Units: hours
        median (inter-quartile range (Q1-Q3))
    57.3 (32.4 to 75.6)
    37.2 (25.6 to 81.4)
    No statistical analyses for this end point

    Secondary: Secondary outcome 1 – Readiness for SBT - Frequency of the SBT criteria being met per participant

    Close Top of page
    End point title
    Secondary outcome 1 – Readiness for SBT - Frequency of the SBT criteria being met per participant
    End point description
    End point type
    Secondary
    End point timeframe
    Date/time of randomisation to the date/time of the observation at which readiness for SBT is first reported.
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    115
    117
    Units: Total occurrences of SBT readiness
        0 occurences of SBT readiness
    17
    13
        1 occurence of SBT readiness
    71
    63
        2 occurences of SBT readiness
    20
    25
        3 occurences of SBT readiness
    4
    8
        4 occurences of SBT readiness
    1
    5
        5 occurences of SBT readiness
    2
    3
    No statistical analyses for this end point

    Secondary: Secondary outcome 1 – Readiness for SBT - Two-sample t-test for log time to SBT in hours

    Close Top of page
    End point title
    Secondary outcome 1 – Readiness for SBT - Two-sample t-test for log time to SBT in hours
    End point description
    End point type
    Secondary
    End point timeframe
    Date/time of randomisation to the date/time of the observation at which readiness for SBT is first reported.
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    98
    104
    Units: log hours
        arithmetic mean (confidence interval 95%)
    3.78 (3.55 to 4.00)
    3.79 (3.61 to 3.97)
    Statistical analysis title
    Endotracheal poractant alfa- Sham Intervention
    Statistical analysis description
    Result for two-sample t-test for log time to SBT in hours Difference (Endotracheal poractant alfa- Sham Intervention group)
    Comparison groups
    Endotracheal poractant alfa v Sham Intervention group
    Number of subjects included in analysis
    202
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.9373
    Method
    t-test, 2-sided
    Parameter type
    Mean difference (final values)
    Point estimate
    -0.01
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.29
         upper limit
    0.27

    Secondary: Secondary outcome 1 – sensitivity analysis: First SBT criteria - two-sample t-test for time to SBT: sensitivity analysis

    Close Top of page
    End point title
    Secondary outcome 1 – sensitivity analysis: First SBT criteria - two-sample t-test for time to SBT: sensitivity analysis
    End point description
    End point type
    Secondary
    End point timeframe
    Date/time of randomisation to the date/time of the observation at which readiness for SBT is first reported.
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    98
    104
    Units: log hours
        arithmetic mean (confidence interval 95%)
    3.78 (3.55 to 4.00)
    3.80 (3.61 to 3.98)
    Statistical analysis title
    Endotracheal poractant alfa- Sham Intervention
    Statistical analysis description
    Result for two-sample t-test for time to SBT: sensitivity analysis Difference (Endotracheal poractant alfa- Sham Intervention group)
    Comparison groups
    Sham Intervention group v Endotracheal poractant alfa
    Number of subjects included in analysis
    202
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.8994
    Method
    t-test, 2-sided
    Parameter type
    Mean difference (final values)
    Point estimate
    -0.02
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.3
         upper limit
    0.27

    Secondary: Secondary outcome 2 – Number of trial interventions - Frequency of trial interventions

    Close Top of page
    End point title
    Secondary outcome 2 – Number of trial interventions - Frequency of trial interventions
    End point description
    A more extensive summary of results for this outcome can be found in the attached BESS - Final_Analysis_Report_v5.0_20260311.pdf.
    End point type
    Secondary
    End point timeframe
    add
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    115
    117
    Units: Total trial interventions
        0 trial interventions
    6
    3
        1 trial intervention
    17
    10
        2 trial interventions
    17
    21
        3 trial interventions
    75
    83
    Statistical analysis title
    Fishers exact
    Comparison groups
    Endotracheal poractant alfa v Sham Intervention group
    Number of subjects included in analysis
    232
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.3166
    Method
    Fisher exact
    Confidence interval

    Secondary: Secondary outcome 4 – Duration of oxygen supplementation - Time on oxygen supplementation (of any kind) - Mean (S.D.)

    Close Top of page
    End point title
    Secondary outcome 4 – Duration of oxygen supplementation - Time on oxygen supplementation (of any kind) - Mean (S.D.)
    End point description
    A more extensive summary of results for this outcome can be found in the attached BESS - Final_Analysis_Report_v5.0_20260311.pdf.
    End point type
    Secondary
    End point timeframe
    Date and time of final successful extubation (if this has been observed) to final date and time that any type of oxygen supplementation is ended.
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    115
    117
    Units: Time on oxygen supplementation (hours)
        arithmetic mean (standard deviation)
    280.9 ( 2455.2 )
    58.4 ( 74.2 )
    No statistical analyses for this end point

    Secondary: Secondary outcome 4 – Duration of oxygen supplementation - Time on oxygen supplementation (of any kind) - Median (IQR)

    Close Top of page
    End point title
    Secondary outcome 4 – Duration of oxygen supplementation - Time on oxygen supplementation (of any kind) - Median (IQR)
    End point description
    End point type
    Secondary
    End point timeframe
    Date and time of final successful extubation (if this has been observed) to final date and time that any type of oxygen supplementation is ended.
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    115
    117
    Units: Time on oxygen supplementation (hours)
        median (inter-quartile range (Q1-Q3))
    40.9 (17.0 to 90.0)
    34.0 (16.0 to 81.4)
    No statistical analyses for this end point

    Secondary: Secondary outcome 4 – Duration of oxygen supplementation - Time on oxygen supplementation (of any kind) - Median (Range)

    Close Top of page
    End point title
    Secondary outcome 4 – Duration of oxygen supplementation - Time on oxygen supplementation (of any kind) - Median (Range)
    End point description
    End point type
    Secondary
    End point timeframe
    Date and time of final successful extubation (if this has been observed) to final date and time that any type of oxygen supplementation is ended.
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    115
    117
    Units: Time on oxygen supplementation (hours)
        median (full range (min-max))
    40.9 (0.0 to 26376.3)
    34.0 (0.0 to 536.5)
    No statistical analyses for this end point

    Secondary: Secondary outcome 4 – Duration of oxygen supplementation - Results of two-sample t-test for duration of oxygen supplementation

    Close Top of page
    End point title
    Secondary outcome 4 – Duration of oxygen supplementation - Results of two-sample t-test for duration of oxygen supplementation
    End point description
    End point type
    Secondary
    End point timeframe
    Date and time of final successful extubation (if this has been observed) to final date and time that any type of oxygen supplementation is ended.
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    115
    117
    Units: log hours
        arithmetic mean (confidence interval 95%)
    3.07 (2.58 to 3.56)
    2.18 (1.48 to 2.89)
    Statistical analysis title
    Endotracheal poractant alfa- Sham Intervention
    Statistical analysis description
    Results of two-sample t-test for duration of oxygen supplementation: Difference (Endotracheal poractant alfa- Sham Intervention group)
    Comparison groups
    Endotracheal poractant alfa v Sham Intervention group
    Number of subjects included in analysis
    232
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.0428
    Method
    t-test, 2-sided
    Parameter type
    Mean difference (final values)
    Point estimate
    0.88
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.03
         upper limit
    1.74

    Secondary: Secondary outcome 5 – Use of steroids to assist extubation - Frequency of steroid use

    Close Top of page
    End point title
    Secondary outcome 5 – Use of steroids to assist extubation - Frequency of steroid use
    End point description
    End point type
    Secondary
    End point timeframe
    add
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    115
    117
    Units: No. participants
        Yes
    51
    49
        No
    64
    68
    Statistical analysis title
    Pearson's Chi-Square test
    Comparison groups
    Endotracheal poractant alfa v Sham Intervention group
    Number of subjects included in analysis
    232
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.7044
    Method
    Chi-squared
    Parameter type
    Risk ratio (RR)
    Point estimate
    1.06
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.79
         upper limit
    1.42

    Secondary: Secondary outcome 6 - Time on post-extubation respiratory support (non-invasive) - Mean (S.D.)

    Close Top of page
    End point title
    Secondary outcome 6 - Time on post-extubation respiratory support (non-invasive) - Mean (S.D.)
    End point description
    A more extensive summary of results for this outcome can be found in the attached BESS - Final_Analysis_Report_v5.0_20260311.pdf.
    End point type
    Secondary
    End point timeframe
    Date and time of final successful extubation (if this has been observed) to final date and time that NIV is ended.
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    115
    117
    Units: Hours
        arithmetic mean (standard deviation)
    17.1 ( 34.1 )
    19.5 ( 48.6 )
    No statistical analyses for this end point

    Secondary: Secondary outcome 6 - Time on post-extubation respiratory support (non-invasive) - Median (IQR)

    Close Top of page
    End point title
    Secondary outcome 6 - Time on post-extubation respiratory support (non-invasive) - Median (IQR)
    End point description
    End point type
    Secondary
    End point timeframe
    Date and time of final successful extubation (if this has been observed) to final date and time that NIV is ended.
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    115
    117
    Units: Hours
        median (inter-quartile range (Q1-Q3))
    0.0 (0.0 to 15.7)
    0.0 (0.0 to 0.0)
    No statistical analyses for this end point

    Secondary: Secondary outcome 6 - Time on post-extubation respiratory support (non-invasive) - Median (Range)

    Close Top of page
    End point title
    Secondary outcome 6 - Time on post-extubation respiratory support (non-invasive) - Median (Range)
    End point description
    End point type
    Secondary
    End point timeframe
    Date and time of final successful extubation (if this has been observed) to final date and time that NIV is ended.
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    115
    117
    Units: Hours
        median (full range (min-max))
    0.0 (0.0 to 146.0)
    0.0 (0.0 to 285.5)
    No statistical analyses for this end point

    Secondary: Secondary outcome 6 - Results of two-sample t-test for duration of post-extubation respiratory support

    Close Top of page
    End point title
    Secondary outcome 6 - Results of two-sample t-test for duration of post-extubation respiratory support
    End point description
    End point type
    Secondary
    End point timeframe
    Date and time of final successful extubation (if this has been observed) to final date and time that NIV is ended.
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    115
    117
    Units: log hours
        arithmetic mean (confidence interval 95%)
    -3.73 (-4.63 to -2.82)
    -4.24 (-5.11 to -3.38)
    Statistical analysis title
    Endotracheal poractant alfa- Sham Intervention
    Statistical analysis description
    Results of two-sample t-test for duration of post-extubation respiratory support: Difference (Endotracheal poractant alfa- Sham Intervention group)
    Comparison groups
    Endotracheal poractant alfa v Sham Intervention group
    Number of subjects included in analysis
    232
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.4125
    Method
    t-test, 2-sided
    Parameter type
    Mean difference (final values)
    Point estimate
    0.52
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.72
         upper limit
    1.76

    Secondary: Secondary outcome 7 - Time in PICU - Mean (S.D.)

    Close Top of page
    End point title
    Secondary outcome 7 - Time in PICU - Mean (S.D.)
    End point description
    A more extensive summary of results for this outcome can be found in the attached BESS - Final_Analysis_Report_v5.0_20260311.pdf.
    End point type
    Secondary
    End point timeframe
    Date/time of randomisation to the date/ time of discharge from PICU or the date of death if the death occurred before PICU discharge.
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    114
    116
    Units: Hours
        arithmetic mean (standard deviation)
    121.6 ( 80.9 )
    134.8 ( 198.0 )
    No statistical analyses for this end point

    Secondary: Secondary outcome 7 - Time in PICU - Median (IQR)

    Close Top of page
    End point title
    Secondary outcome 7 - Time in PICU - Median (IQR)
    End point description
    End point type
    Secondary
    End point timeframe
    Date/time of randomisation to the date/ time of discharge from PICU or the date of death if the death occurred before PICU discharge.
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    114
    116
    Units: Hours
        median (inter-quartile range (Q1-Q3))
    104.4 (67.9 to 153.1)
    93.4 (66.6 to 144.8)
    No statistical analyses for this end point

    Secondary: Secondary outcome 7 - Time in PICU - Median (Range)

    Close Top of page
    End point title
    Secondary outcome 7 - Time in PICU - Median (Range)
    End point description
    End point type
    Secondary
    End point timeframe
    Date/time of randomisation to the date/ time of discharge from PICU or the date of death if the death occurred before PICU discharge.
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    114
    116
    Units: Hours
        median (full range (min-max))
    104.4 (17.9 to 571.7)
    93.4 (24.4 to 2095.9)
    No statistical analyses for this end point

    Secondary: Secondary outcome 7 - Time in hospital (including both time in PICU and time in hospital) - Mean (S.D.)

    Close Top of page
    End point title
    Secondary outcome 7 - Time in hospital (including both time in PICU and time in hospital) - Mean (S.D.)
    End point description
    End point type
    Secondary
    End point timeframe
    Date/time of randomisation to the date/time of hospital discharge or the date of death if death occurred before hospital discharge.
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    113
    114
    Units: Hours
        arithmetic mean (standard deviation)
    200.8 ( 174.3 )
    171.2 ( 100.5 )
    No statistical analyses for this end point

    Secondary: Secondary outcome 7 - Time in hospital (including both time in PICU and time in hospital) - Median (IQR)

    Close Top of page
    End point title
    Secondary outcome 7 - Time in hospital (including both time in PICU and time in hospital) - Median (IQR)
    End point description
    End point type
    Secondary
    End point timeframe
    Date/time of randomisation to the date/time of hospital discharge or the date of death if death occurred before hospital discharge.
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    113
    114
    Units: Hours
        median (inter-quartile range (Q1-Q3))
    165.3 (111.3 to 231.2)
    142.2 (96.6 to 221.9)
    No statistical analyses for this end point

    Secondary: Secondary outcome 7 - Time in hospital (including both time in PICU and time in hospital) - Median (Range)

    Close Top of page
    End point title
    Secondary outcome 7 - Time in hospital (including both time in PICU and time in hospital) - Median (Range)
    End point description
    End point type
    Secondary
    End point timeframe
    Date/time of randomisation to the date/time of hospital discharge or the date of death if death occurred before hospital discharge.
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    113
    114
    Units: Hours
        median (full range (min-max))
    165.3 (17.9 to 1616.2)
    142.2 (34.3 to 430.8)
    No statistical analyses for this end point

    Secondary: Secondary outcome 7 - Results of two-sample t-test for duration of stay in PICU in hours

    Close Top of page
    End point title
    Secondary outcome 7 - Results of two-sample t-test for duration of stay in PICU in hours
    End point description
    End point type
    Secondary
    End point timeframe
    Date/time of randomisation to the date/ time of discharge from PICU or the date of death if the death occurred before PICU discharge.
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    114
    116
    Units: log hours
        log mean (confidence interval 95%)
    4.62 (4.51 to 4.73)
    4.62 (4.50 to 4.74)
    Statistical analysis title
    Endotracheal poractant alfa- Sham Intervention
    Statistical analysis description
    Results of two-sample t-test for duration of stay in PICU in hours Difference (Endotracheal poractant alfa- Sham Intervention group)
    Comparison groups
    Endotracheal poractant alfa v Sham Intervention group
    Number of subjects included in analysis
    230
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.9453
    Method
    t-test, 2-sided
    Parameter type
    Mean difference (final values)
    Point estimate
    0.01
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.16
         upper limit
    0.17

    Secondary: Secondary outcome 7 - Results of two-sample t-test for duration of stay in hospital (post PICU stay)

    Close Top of page
    End point title
    Secondary outcome 7 - Results of two-sample t-test for duration of stay in hospital (post PICU stay)
    End point description
    End point type
    Secondary
    End point timeframe
    Date/time of discharge from PICU to Date/time of hospital discharge.
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    113
    114
    Units: log hours
        log mean (confidence interval 95%)
    5.09 (4.98 to 5.21)
    4.97 (4.86 to 5.08)
    Statistical analysis title
    Endotracheal poractant alfa- Sham Intervention
    Statistical analysis description
    Results of two-sample t-test for duration of stay in hospital (post PICU stay) Difference (Endotracheal poractant alfa- Sham Intervention group)
    Comparison groups
    Endotracheal poractant alfa v Sham Intervention group
    Number of subjects included in analysis
    227
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.1331
    Method
    t-test, 2-sided
    Parameter type
    Mean difference (final values)
    Point estimate
    0.12
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.04
         upper limit
    0.28

    Secondary: Secondary outcome 8 – Liverpool Respiratory Symptom Questionnaire - Summary of LRSQ data at 6 months - Mean (S.D.)

    Close Top of page
    End point title
    Secondary outcome 8 – Liverpool Respiratory Symptom Questionnaire - Summary of LRSQ data at 6 months - Mean (S.D.)
    End point description
    A more extensive summary of results for this outcome can be found in the attached BESS - Final_Analysis_Report_v5.0_20260311.pdf.
    End point type
    Secondary
    End point timeframe
    At 6 months
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    13
    14
    Units: LRSQ Score
        arithmetic mean (standard deviation)
    22.1 ( 25.9 )
    26.4 ( 27.8 )
    No statistical analyses for this end point

    Secondary: Secondary outcome 8 – Liverpool Respiratory Symptom Questionnaire - Summary of LRSQ data at 6 months - Median (IQR)

    Close Top of page
    End point title
    Secondary outcome 8 – Liverpool Respiratory Symptom Questionnaire - Summary of LRSQ data at 6 months - Median (IQR)
    End point description
    End point type
    Secondary
    End point timeframe
    At 6 months
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    13
    14
    Units: LRSQ Score
        median (inter-quartile range (Q1-Q3))
    12.0 (11.0 to 18.0)
    14.5 (4.0 to 60.0)
    No statistical analyses for this end point

    Secondary: Secondary outcome 8 – Liverpool Respiratory Symptom Questionnaire - Summary of LRSQ data at 6 months - Median (Range)

    Close Top of page
    End point title
    Secondary outcome 8 – Liverpool Respiratory Symptom Questionnaire - Summary of LRSQ data at 6 months - Median (Range)
    End point description
    End point type
    Secondary
    End point timeframe
    At 6 months
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    13
    14
    Units: LRSQ Score
        median (full range (min-max))
    12.0 (0.0 to 80.0)
    14.5 (0.0 to 74.0)
    No statistical analyses for this end point

    Other pre-specified: Safety outcome 1 – Failure to administer intervention due to AE - Frequency of trial interventions not delivered due to AE

    Close Top of page
    End point title
    Safety outcome 1 – Failure to administer intervention due to AE - Frequency of trial interventions not delivered due to AE
    End point description
    End point type
    Other pre-specified
    End point timeframe
    add
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    115
    117
    Units: Participants
        0 trial interventions not delivered
    112
    117
        1 trial intervention not delivered
    3
    0
    Statistical analysis title
    Fisher's Exact Test
    Comparison groups
    Endotracheal poractant alfa v Sham Intervention group
    Number of subjects included in analysis
    232
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.1202
    Method
    Fisher exact
    Confidence interval

    Other pre-specified: Safety outcome 2 – Incidence of air leak - Frequency of the total incidences or air leak per participant

    Close Top of page
    End point title
    Safety outcome 2 – Incidence of air leak - Frequency of the total incidences or air leak per participant
    End point description
    End point type
    Other pre-specified
    End point timeframe
    add
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    115
    117
    Units: Participants
        0 incidences of air leaks
    114
    116
        1 incidence of air leak
    1
    1
    Statistical analysis title
    Fisher's Exact Test
    Comparison groups
    Endotracheal poractant alfa v Sham Intervention group
    Number of subjects included in analysis
    232
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 1
    Method
    Fisher exact
    Confidence interval

    Other pre-specified: Safety outcome 3 – Parent reported readmission to hospital - Frequency of the total reported readmissions to hospital

    Close Top of page
    End point title
    Safety outcome 3 – Parent reported readmission to hospital - Frequency of the total reported readmissions to hospital
    End point description
    End point type
    Other pre-specified
    End point timeframe
    add
    End point values
    Endotracheal poractant alfa (patient reported readmission) Sham Intervention group (patient reported readmission)
    Number of subjects analysed
    26
    28
    Units: Participants
        0 readmissions
    15
    23
        1 readmission
    6
    5
        2 readmissions
    1
    0
        3 readmissions
    4
    0
        4 readmissions
    0
    0
        5 readmissions
    0
    0
        >=6 readmissions
    0
    0
    Statistical analysis title
    Fisher's Exact Test
    Comparison groups
    Endotracheal poractant alfa (patient reported readmission) v Sham Intervention group (patient reported readmission)
    Number of subjects included in analysis
    54
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.0561
    Method
    Fisher exact
    Confidence interval

    Other pre-specified: Safety outcome 4 – Any need to replace the endotracheal tube - Frequency of endotracheal tubes replacements

    Close Top of page
    End point title
    Safety outcome 4 – Any need to replace the endotracheal tube - Frequency of endotracheal tubes replacements
    End point description
    End point type
    Other pre-specified
    End point timeframe
    add
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    115
    117
    Units: Participants
        Endotracheal tube replaced: Yes
    18
    21
        Endotracheal tube replaced: No
    97
    96
    Statistical analysis title
    Pearson's Chi-Square test
    Comparison groups
    Endotracheal poractant alfa v Sham Intervention group
    Number of subjects included in analysis
    232
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.64
    Method
    Chi-squared
    Parameter type
    Risk ratio (RR)
    Point estimate
    0.87
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.49
         upper limit
    1.55

    Post-hoc: Virology – post-hoc request - Virology reported on the discharge CRF

    Close Top of page
    End point title
    Virology – post-hoc request - Virology reported on the discharge CRF
    End point description
    End point type
    Post-hoc
    End point timeframe
    Virology reported on the discharge CRF
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    115
    117
    Units: Participants
        Adenovirus
    3
    6
        Coronavirus OC43
    0
    1
        Enterovirus
    5
    8
        Influenza A
    0
    2
        Influenza A/H1
    0
    1
        Influenza B
    0
    1
        Metapneumovirus
    2
    5
        No Infection Identified
    8
    5
        No Sample
    4
    0
        No form returned
    2
    1
        Parainfluenza 1
    1
    0
        Parainfluenza 3
    1
    1
        Parainfluenza 4
    1
    0
        Respiratory Syncytial virus
    87
    88
        Rhinovirus
    21
    29
        SARS-CoV-2 (COVID-19)
    1
    1
    No statistical analyses for this end point

    Post-hoc: Bacteriology – post-hoc request - Bacteriology reported on the discharge CRF

    Close Top of page
    End point title
    Bacteriology – post-hoc request - Bacteriology reported on the discharge CRF
    End point description
    End point type
    Post-hoc
    End point timeframe
    Bacteriology reported on the discharge CRF
    End point values
    Endotracheal poractant alfa Sham Intervention group
    Number of subjects analysed
    115
    117
    Units: Participants
        Haemophilus influenzae
    18
    17
        No Infection Identified
    79
    82
        No Sample
    4
    2
        No form returned
    4
    4
        Normal flora
    3
    0
        Staphylococcus aureus
    5
    12
        Strep. Pneumonia (group B strep.)
    4
    3
    No statistical analyses for this end point

    Post-hoc: Safety outcome data by safety set – Post hoc - Safety outcome 1 - Frequency of trial interventions not delivered due to AE

    Close Top of page
    End point title
    Safety outcome data by safety set – Post hoc - Safety outcome 1 - Frequency of trial interventions not delivered due to AE
    End point description
    End point type
    Post-hoc
    End point timeframe
    add
    End point values
    Endotracheal poractant alfa (Safety set) Sham Intervention group (Safety set)
    Number of subjects analysed
    109
    114
    Units: Participants
        0 trial interventions not delivered:
    107
    114
        1 trial intervention not delivered:
    2
    0
    Statistical analysis title
    Fisher's Exact Test
    Comparison groups
    Endotracheal poractant alfa (Safety set) v Sham Intervention group (Safety set)
    Number of subjects included in analysis
    223
    Analysis specification
    Post-hoc
    Analysis type
    superiority
    P-value
    = 0.2378
    Method
    Fisher exact
    Confidence interval

    Post-hoc: Safety outcome data by safety set – Post hoc - Safety outcome 2 - Frequency of the total incidences or air leak per participant

    Close Top of page
    End point title
    Safety outcome data by safety set – Post hoc - Safety outcome 2 - Frequency of the total incidences or air leak per participant
    End point description
    End point type
    Post-hoc
    End point timeframe
    add
    End point values
    Endotracheal poractant alfa (Safety set) Sham Intervention group (Safety set)
    Number of subjects analysed
    109
    114
    Units: Participants
        0 incidences of air leaks:
    108
    113
        1 incidence of air leaks:
    1
    1
    Statistical analysis title
    Fisher's Exact Test
    Comparison groups
    Endotracheal poractant alfa (Safety set) v Sham Intervention group (Safety set)
    Number of subjects included in analysis
    223
    Analysis specification
    Post-hoc
    Analysis type
    superiority
    P-value
    = 1
    Method
    Fisher exact
    Confidence interval

    Post-hoc: Safety outcome data by safety set – Post hoc - Safety outcome 3 - Frequency of the total reported readmissions to hospital

    Close Top of page
    End point title
    Safety outcome data by safety set – Post hoc - Safety outcome 3 - Frequency of the total reported readmissions to hospital
    End point description
    End point type
    Post-hoc
    End point timeframe
    add
    End point values
    Endotracheal poractant alfa (Safety set) Sham Intervention group (Safety set)
    Number of subjects analysed
    26
    28
    Units: Participants
        0 readmissions:
    15
    23
        1 readmission:
    6
    5
        2 readmissions:
    1
    0
        3 readmissions:
    4
    0
        4 readmissions:
    0
    0
        5 readmissions:
    0
    0
        >=6 readmissions:
    0
    0
    Statistical analysis title
    Fisher's Exact Test
    Comparison groups
    Endotracheal poractant alfa (Safety set) v Sham Intervention group (Safety set)
    Number of subjects included in analysis
    54
    Analysis specification
    Post-hoc
    Analysis type
    superiority
    P-value
    = 0.0561
    Method
    Fisher exact
    Confidence interval

    Post-hoc: Safety outcome data by safety set – Post hoc - Safety outcome 4 – Any need to replace the endotracheal tube

    Close Top of page
    End point title
    Safety outcome data by safety set – Post hoc - Safety outcome 4 – Any need to replace the endotracheal tube
    End point description
    End point type
    Post-hoc
    End point timeframe
    add
    End point values
    Endotracheal poractant alfa (Safety set) Sham Intervention group (Safety set)
    Number of subjects analysed
    109
    114
    Units: Participants
        Endotracheal tube replaced: Yes
    18
    20
        Endotracheal tube replaced: No
    91
    94
    Statistical analysis title
    Pearson's Chi-Square test
    Comparison groups
    Endotracheal poractant alfa (Safety set) v Sham Intervention group (Safety set)
    Number of subjects included in analysis
    223
    Analysis specification
    Post-hoc
    Analysis type
    superiority
    P-value
    = 0.838
    Method
    Chi-squared
    Parameter type
    Risk ratio (RR)
    Point estimate
    0.94
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.53
         upper limit
    1.68

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    All AEs from randomisation until 24 hrs after last administration of poractant alfa are reported. Related AEs occurring after this time point until 90 days post randomisation / discharge / death are reported. SAEs/SARs are reported regardless of timeframe
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    24.0
    Reporting groups
    Reporting group title
    Endotracheal poractant alfa (Safety set)
    Reporting group description
    -

    Reporting group title
    Sham Intervention group (Safety set)
    Reporting group description
    -

    Serious adverse events
    Endotracheal poractant alfa (Safety set) Sham Intervention group (Safety set)
    Total subjects affected by serious adverse events
         subjects affected / exposed
    6 / 109 (5.50%)
    6 / 114 (5.26%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Injury, poisoning and procedural complications
    Endotracheal intubation complication
         subjects affected / exposed
    0 / 109 (0.00%)
    1 / 114 (0.88%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac disorders
    Bradycardia
         subjects affected / exposed
    0 / 109 (0.00%)
    1 / 114 (0.88%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac arrest
         subjects affected / exposed
    1 / 109 (0.92%)
    0 / 114 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Hypoxia
         subjects affected / exposed
    1 / 109 (0.92%)
    0 / 114 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Obliterative bronchiolitis
         subjects affected / exposed
    0 / 109 (0.00%)
    1 / 114 (0.88%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumothorax
         subjects affected / exposed
    1 / 109 (0.92%)
    1 / 114 (0.88%)
         occurrences causally related to treatment / all
    1 / 1
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulmonary haemorrhage
         subjects affected / exposed
    1 / 109 (0.92%)
    0 / 114 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Adenovirus infection
         subjects affected / exposed
    0 / 109 (0.00%)
    1 / 114 (0.88%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bronchiolitis
         subjects affected / exposed
    2 / 109 (1.83%)
    0 / 114 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Parainfluenzae virus infection
         subjects affected / exposed
    1 / 109 (0.92%)
    0 / 114 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    0 / 109 (0.00%)
    1 / 114 (0.88%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Endotracheal poractant alfa (Safety set) Sham Intervention group (Safety set)
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    14 / 109 (12.84%)
    8 / 114 (7.02%)
    Investigations
    Oxygen saturation decreased
         subjects affected / exposed
    4 / 109 (3.67%)
    0 / 114 (0.00%)
         occurrences all number
    5
    0
    Injury, poisoning and procedural complications
    Endotracheal intubation complication
         subjects affected / exposed
    1 / 109 (0.92%)
    1 / 114 (0.88%)
         occurrences all number
    1
    1
    Sedation complication
         subjects affected / exposed
    1 / 109 (0.92%)
    0 / 114 (0.00%)
         occurrences all number
    1
    0
    Cardiac disorders
    Bradycardia
         subjects affected / exposed
    4 / 109 (3.67%)
    0 / 114 (0.00%)
         occurrences all number
    4
    0
    Surgical and medical procedures
    Extubation
         subjects affected / exposed
    2 / 109 (1.83%)
    1 / 114 (0.88%)
         occurrences all number
    2
    1
    Nervous system disorders
    Epilepsy
         subjects affected / exposed
    0 / 109 (0.00%)
    1 / 114 (0.88%)
         occurrences all number
    0
    1
    General disorders and administration site conditions
    Perforation
         subjects affected / exposed
    0 / 109 (0.00%)
    1 / 114 (0.88%)
         occurrences all number
    0
    1
    Pyrexia
         subjects affected / exposed
    0 / 109 (0.00%)
    1 / 114 (0.88%)
         occurrences all number
    0
    1
    Ear and labyrinth disorders
    Otorrhoea
         subjects affected / exposed
    0 / 109 (0.00%)
    1 / 114 (0.88%)
         occurrences all number
    0
    1
    Reproductive system and breast disorders
    Genital discharge
         subjects affected / exposed
    1 / 109 (0.92%)
    0 / 114 (0.00%)
         occurrences all number
    1
    0
    Respiratory, thoracic and mediastinal disorders
    Atelectasis
         subjects affected / exposed
    0 / 109 (0.00%)
    1 / 114 (0.88%)
         occurrences all number
    0
    1
    Hypoxia
         subjects affected / exposed
    0 / 109 (0.00%)
    1 / 114 (0.88%)
         occurrences all number
    0
    1
    Respiratory depth decreased
         subjects affected / exposed
    1 / 109 (0.92%)
    0 / 114 (0.00%)
         occurrences all number
    1
    0
    Infections and infestations
    Bronchiolitis
         subjects affected / exposed
    0 / 109 (0.00%)
    1 / 114 (0.88%)
         occurrences all number
    0
    1
    Pneumonia
         subjects affected / exposed
    1 / 109 (0.92%)
    0 / 114 (0.00%)
         occurrences all number
    1
    0
    Metabolism and nutrition disorders
    Hypokalaemia
         subjects affected / exposed
    1 / 109 (0.92%)
    0 / 114 (0.00%)
         occurrences all number
    1
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    31 Jul 2019
    Amendment from Protocol V2.0 to V3.0 - See section 18.3 of attached BESS Protocol V7.0 for a summary of amendments.
    24 Nov 2022
    Amendment from Protocol V3.0 to V4.0 - See section 18.4 of attached BESS Protocol V7.0 for a summary of amendments.
    07 Feb 2023
    Amendment from Protocol V4.0 to V5.0 - See section 18.5 of attached BESS Protocol V7.0 for a summary of amendments.

    Interruptions (globally)

    Were there any global interruptions to the trial? Yes
    Date
    Interruption
    Restart date
    20 Mar 2020
    There was a temporary halt to recruitment from 20/03/2020 until 01/10/2020 due to COVID-19.
    01 Oct 2020

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    Results for a primary outcome sensitivity analysis and for Secondary outcome 3 - Change over time in blood/ gas measurements are not included in this summary but results are provided in the attached "BESS - Final_Analysis_Report_v5.0_20260311.pdf"
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Nov 20 01:58:21 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA